PLEASE CLICK HERE TO PROVIDE YOUR CONTACT INFORMATION NEW YORK, Nov. 22, 2024 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP ("Wolf Haldenstein"), a preeminent national shareholder rights litigation firm, announces that is investigating potential claims against Quanterix Corporation (“Quanterix” or the “Company”) (NASDAQ:QTRX) on behalf of Quanterix stockholders. The investigation concerns whether Quanterix and certain of its officers and/or directors have engaged in securities fraud.    PLEA ...

Company Investigation - Bragar Eagel & Squire, P C is investigating potential claims against Quanterix Corporation on behalf of its stockholders regarding potential violations of federal securities laws and/or unlawful business practices [1] Financial Disclosure - Quanterix disclosed an error in the capitalization of labor and overhead costs for prior periods dating back to at least 2021, impacting inventory valuation [2] - The company advised that financial statements containing these errors should no longer be considered reliable [2] - Following the disclosure, Quanterix's stock price fell by 18 3%, closing at $12 40 per share on November 13, 2024 [2] Legal Contact Information - Investors affected by the Quanterix situation can contact Brandon Walker or Marion Passmore at Bragar Eagel & Squire, P C for more information or to discuss their rights and interests [3][5]

Core Viewpoint - Quanterix Corporation is facing potential securities claims due to a significant error in the capitalization of labor and overhead costs, which has adversely affected its financial statements and led to a 19% drop in stock value [2]. Group 1: Company Overview - Quanterix Corporation (NASDAQ: QTRX) is under investigation by Girard Sharp, LLP for potential securities claims on behalf of its investors [1]. - The company announced on November 12, 2024, that it discovered an error in the capitalization of labor and overhead costs dating back to at least 2021, impacting the validity of its financial statements [2]. Group 2: Financial Impact - The error in financial reporting has significantly impacted the value of Quanterix's inventory, raising concerns about the reliability of its financial statements [2]. - Following the announcement of the error, Quanterix's stock price dropped by 19% [2]. Group 3: Legal Representation - Girard Sharp, LLP has a history of representing investors in class actions and complex litigation, including a recent $36.5 million securities settlement against Maxar Technologies [4]. - The firm has been recognized for its work in securities and class action litigation, earning top-tier rankings and accolades [4].

Core Insights - Holzer & Holzer, LLC is investigating Quanterix Corporation for potential violations of federal securities laws following the company's announcement of a need to restate financial statements due to errors in capitalizing labor and overhead costs [1] - The restatement affects financial periods dating back to at least 2021 and has implications for the valuation of inventory [1] - Following the announcement, Quanterix's stock price experienced a decline [1] Company Overview - Quanterix Corporation trades on NASDAQ under the ticker QTRX [1] - The company is facing scrutiny due to its financial reporting practices, which may have misrepresented its financial health [1] Legal Context - Holzer & Holzer, LLC is a law firm specializing in securities litigation, representing shareholders and investors in cases of corporate misconduct [3] - The firm has a history of recovering significant amounts for shareholders affected by fraud [3]

Nadya Tkach/iStock via Getty Images It has been more than nine months since we last took a look at life sciences company Quanterix Corporation (NASDAQ:QTRX). It was also the last time this smallcap company was covered here on Seeking Alpha. We concluded our last piece on this firm stating the stock was only appropriate for aggressive investors, even as the company had beaten expectations with its last two quarterly earnings reports. It is now time to circle back to Quanterix Corporation. An updated analysis ...

Financial Performance - Quanterix Corporation reported a quarterly loss of $0.25 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.23, and compared to a loss of $0.16 per share a year ago, indicating an earnings surprise of -8.70% [1] - The company posted revenues of $34.38 million for the quarter ended June 2024, surpassing the Zacks Consensus Estimate by 0.56%, and showing an increase from year-ago revenues of $31.03 million [2] Stock Performance - Quanterix shares have declined approximately 53.8% since the beginning of the year, contrasting with the S&P 500's gain of 9% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.20 on revenues of $36.42 million, and for the current fiscal year, it is -$0.87 on revenues of $141.34 million [7] Industry Outlook - The Medical - Products industry, to which Quanterix belongs, is currently ranked in the top 34% of over 250 Zacks industries, suggesting that companies in the top 50% outperform those in the bottom 50% by more than 2 to 1 [8]

Zacks Consensus Estimate The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period. The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts revising their estimates right before ...

Quanterix Corporation (QTRX) closed the last trading session at $16.82, gaining 5.5% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $28.20 indicates a 67.7% upside potential. The average comprises five short-term price targets ranging from a low of $20 to a high of $34, with a standard deviation of $5.67. While the lowest estimate indicates an increase of 18.9% from the current pr ...

Revenue and Profitability - Total revenues increased by $3.6 million, or 13%, to $32.1 million for the three months ended March 31, 2024, compared to $28.5 million for the same period in 2023[121] - Product revenue was $19.7 million, consisting of instrument sales of $2.6 million and consumables sales of $17.1 million, representing a 2% increase compared to $19.3 million in the prior year[122] - Service revenue increased by $3.4 million, or 39%, to $12.0 million, primarily driven by a $3.2 million increase in Accelerator Laboratory revenue[123] - Gross profit for the three months ended March 31, 2024, was $19.6 million, representing a gross margin of 61%, compared to a gross profit of $16.9 million and a margin of 59% in the prior year[119] - GAAP gross profit for the three months ended March 31, 2024, was $19.6 million, compared to $16.9 million for the same period in 2023[152] - GAAP revenue increased to $32.1 million for the three months ended March 31, 2024, from $28.5 million in the same period in 2023[152] - Non-GAAP gross margin improved to 54.5% for the three months ended March 31, 2024, compared to 53.1% for the same period in 2023[152] Expenses and Losses - Research and development expenses increased by $2.0 million, or 41%, to $6.7 million, primarily due to increased headcount and professional services[127] - Operating expenses rose by $7.2 million, or 28%, to $33.6 million, leading to a loss from operations of $14.0 million for the three months ended March 31, 2024[119] - The net loss for the three months ended March 31, 2024, was $10.1 million, compared to a net loss of $6.1 million for the same period in 2023, reflecting a 65% increase in losses[119] - Selling, general and administrative expenses increased by $5.1 million, or 25%, to $26.0 million for the three months ended March 31, 2024, compared to $20.9 million for the same period in 2023[128] Cash and Investments - As of March 31, 2024, the company had cash, cash equivalents, and marketable securities totaling $301.9 million[115] - As of March 31, 2024, the company had cash and cash equivalents of $45.3 million and $256.6 million in available-for-sale marketable securities[133] - The company expects its cash and marketable securities will be sufficient to meet operating cash requirements for at least 12 months from the date of the report[134] - Net cash used in operating activities was $20.2 million for the three months ended March 31, 2024, compared to $9.5 million for the same period in 2023, reflecting an increase of $10.7 million[142] - Net cash used in investing activities was $109.2 million during the three months ended March 31, 2024, primarily from the purchase of $137.9 million of marketable securities[144] Future Outlook - The company expects to incur significant expenses and operating losses at least through the next 24 months as it expands sales, marketing, and research efforts[116] - The company is actively assessing potential acquisitions to complement its business and may need to raise additional capital if existing resources are insufficient[136] Regulatory and Product Development - The Lucent AD p-Tau 217 blood test received Breakthrough Device designation from the FDA in March 2024, aimed at aiding in the diagnostic evaluation of Alzheimer's disease risk[117] - Interest income rose by $0.5 million, or 14%, to $3.9 million for the three months ended March 31, 2024, due to higher interest rates on cash and marketable securities[130]

Quanterix Corporation (NASDAQ:QTRX) Q1 2024 Earnings Conference Call May 8, 2024 8:30 AM ET Company Participants Francis Pruell - Investor Relations Masoud Toloue - President and Chief Executive Officer Vandana Sriram - Chief Financial Officer Conference Call Participants Puneet Souda - Leerink Partners Matt Sykes - Goldman Sachs Kyle Mikson - Canaccord Genuity Sung Ji Nam - Scotiabank Dan Brennan - TD Cowen Operator Good day and thank you for standing by. Welcome to the Quanterix Corporation Q1 2024 Earnin ...